CardioSource WorldNews July 2015 | Page 28

the causes are multifactorial and likely related to the rapid adoption of LVADs for DT since 2010. In their recent review, Mancini and Colombo listed the possible causes: “Less frequent use of perioperative heparin use, lower target INR ranges due to the high incidence of bleeding, inadequate antiplatelet therapy, overestimate of effective anticoagulation by the partial prothrombin time, abnormal angulation of inflow or outflow cannulas, infection, use of erythropoeietic factors, and/or other factors not yet identified.” “The noise level seems to be somewhat down in the thrombus issue,” said Thoratec CEO Keith Grossman in a quarterly (Q3) 2014 earnings call, but it adds to the overall adverse event issue. “The discussion that I’m hearing is no longer really about one specific type of adverse event, with one pump, but adverse events generally speaking and where we are now and where we should be as an industry.” Another adverse event relates to the deleterious cognitive effects of LVADs. Timothy Fendler, MD, Saint Luke’s Mid America Heart Institute, Kansas City, MO, and colleagues just reported using the Interagency Registry for Mechanically Assisted Circulatory Support to evaluate cognitive function in nearly 1,200 patients who underwent LVAD implantation.9 The cumulative incidence of cognitive decline in the year after LVAD implantation was 29.2%. In adjusted analysis, older age (≥70 versus <50 years; hazard ratio, 2.24) and destination therapy (hazard ratio, 1.42) were significantly associated with greater risk of cognitive decline. The possible mechanism: major, minor, and mini strokes that occur due to blood clots caused by the device. Interestingly, cognition often improved for those patients without cognitive decline, supporting the notion that LVADs improve cerebral perfusion, unless a patient experiences an ischemic event, which is a big if given that these events occur commonly. Brahmajee Nallamothu, MD, MPH, chair of Quality of Care and Outcomes Research for the American Heart Association, said, “We need to understand these complications if we’re going to start broadening their use.” However, he noted that Dr. Fendler’s research only showed an association—not a proven link—between LVADs and mental decline in some patients. “These are really sick patients, and they have a lot of reasons to suffer cognitive decline,” said Dr. Nallamothu. “These are people who otherwise without the device in all likelihood would die within a short time period. That’s a real key point.” A second new study, this one much smaller, looked at 176 LVAD patients who were tested using the MoCA (Montreal Cognitive Assessment), a simple screening tool sensitive to mild cognitive impairment. Pre -LVAD implantation, cognitive impairment was seen in 67% of the study cohort. In the 56 patients re-evaluated at 8 months post-implantation, total MoCA score as well as the visuospacial, executive, and delayed recall cognitive domains were significantly improved as a group.10 Stem Cell Therapies in HF They really don’t seem to work If you are anticipating that cell therapy will get patients out of this mess, you have a long wait ahead. At ACC.15, Robb MacLellan, MD, the Robert A. Bruce Chair in Cardiovascular Research at the University of Washington Medical Center, Seattle, WA, said that while cell therapies have been shown to be beneficial after myocardial infarction (MI) in multiple animal species at multiple times post-MI, there are “very limited data that cell therapies work in established HF models, work on a background of appropriate medical therapy, or are durable.” Indeed, after more than 10 years of research evaluating bone marrow stem cells, he noted: • Engraftment is very poor (typically <1%). • Durability of transplanted cells is questionable. • Improvements in left ventricular function are at most modest. • It is very unlikely that bone marrow-derived cells directly result in myocyte regeneration. But hope springs eternal, and in a late-breaking tri- 26 CardioSource WorldNews als session at the recent Heart Failure 2015 (a meeting of the European Society of Cardiology), a novel gene therapy treatment called JVS-100 was found to improve left ventricular ejection fraction (LVEF) in some patients with ischemic cardiomyopathy and low ejection fraction. The results of the phase II STOP-HF trial were presented by Marc Penn, MD, PhD, founder and chief medical officer of Juventas and director of cardiovascular research and cardiovascular medicine fellowship at Summa Health in Akron, OH, and e-published in the European Heart Journal.1 The JVS-100 gene therapy is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF1). JVS-100 allows cardiac cells to begin expressing SDF-1 protein, which acts as a beacon to attract the patient’s own stem cells to the heart. The STOP-HF randomized, double blind, placebo controlled trial was performed in 93 symptomatic patients with LVEF ≤40%. Patients received either placebo or 15 endomyocardial injections of JVS-100 15 or 30 mg (during a single treatment). The trial missed its primary endpoint of change in composite score (6-minute walk distance and quality of life) at 4 months, but prespecified analy- Another notable adverse event after implantation of a continuous-flow LVAD is gastrointestinal bleeding (GIB). In an abstract presented at Heart Failure 2015, researchers at the University of Texas Health Science Center, Houston, TX, showed that GIBs occur in about 24% of patients receiving CF-LVADs, with no difference in incidence in regard to device type, INTERMACS score, or blood types.11 On regression analysis, the only significant risk factor for GIB was the presence of chronic kidney disease, giving clinicians little information for preventing this adverse event or its recurrence. Continual Technological Evolution There are currently two U.S. Food and Drug Administration (FDA)-approved MCS devices for adults: The HeartMate II (Thoratec Corporation, Pleasanton, California) CF pump (IMAGE 1) was approved for bridge-totransplant therapy (BTT) in 2008 and for DT in 2010. The HeartWare HVAD (HeartWare International, Inc., Framingham, MA; the H stands for HeartWare) was approved for BTT in November 2012. (One pediatric device has also been approved: the MicroMed DeBakey Child ventricular assist device.) Three more second-generation devices—the Jarvik 2000 (Jarvik Heart), Incor (Berlin Heart), and HeartAssist 5 (ReliantHeart)—are commercially available in Europe but investigational in the U.S. In April 2015, Thoratec Corporation announced approval from the FDA to broaden enrollment of its ses demonstrated a greater effect of JVS-100 on patients with higher-risk HF defined by lower ejection fraction. Patients with the worst heart failure who were given the higher dose of the study drug showed a 7% increase in LVEF as compared to a 4% decrease in the placebo group (p < 0.05). “The confluence of change in this group, in LVEF, NTproBNP, LV end-systolic volume, and the composite score and stroke volume are consistent with a meaningful change in high-risk patients,” concluded Dr. Penn. He added that the degree of heart remodeling induced by SDF-1 overexpression should give a greater than 80% chance of mortality benefit in future trials. We’ll see. In mid-May 2015, the U.S. FDA granted JVS-100 Fast Track status and approved a phase IIb, doubleblind, sham-controlled trial of the agent. STOP-HF2 will evaluate the safety and efficacy of two administrations of 30 mg doses of JVS-100 in HF patients with LVEF ≤ 35% and N-terminal pro–B-type natriuretic peptide ≥500 pg/ml. The first dose will be delivered at enrollment and the second 6 months later, each delivered by endomyocardial injection catheter to the left ventricle of the heart. REFERENCE: 1. Chung ES, Miller L, Patel AN, et al. Eur Heart J. 2015; June 7 [Epub ahead of print]. July 2015